Future Prospects of Pain Treatment with Botulinum Neurotoxins
Treatment of pain with botulinum neurotoxins is now entering a new era due to the emergence of newly engineered compounds which by targeting the sensory neurons can offer a more effective means of pain control. The preliminary data from cell culture and animal experiments suggest a significant potential for these toxins/toxin chimeras and toxin/antibody compounds in relieving human pain.
KeywordsBotulinum toxin Botulinum neurotoxin Tetanus toxin A/E chimera Antibody P2X3 receptor Pain
- Burnstock G. Physiopathological roles of p2x receptors in the central nervous system. Curr Med Chem. 2015;22:819–44.Google Scholar
- Ferrari E, Gu C, Niranjan D, Restani L, Rasetti-Escargueil C, Obara I, Geranton SM, Arsenault J, Goetze TA, Harper CB, Nguyen TH, Maywood E, O’Brien J, Schiavo G, Wheeler DW, Meunier FA, Hastings M, Edwardson JM, Sesardic D, Caleo M, Hunt SP, Davletov B. Synthetic self-assembling clostridial chimera for modulation of sensory functions. Bioconjug Chem. 2013;24:1750–9.CrossRefPubMedCentralPubMedGoogle Scholar
- Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, Dolly JO. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–92.CrossRefPubMedGoogle Scholar